|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003316,
umls-concept:C0012854,
umls-concept:C0034861,
umls-concept:C0042196,
umls-concept:C0042210,
umls-concept:C0184511,
umls-concept:C0205314,
umls-concept:C0600139,
umls-concept:C0679622,
umls-concept:C1522673,
umls-concept:C1875307
|
|
pubmed:issue |
39
|
|
pubmed:dateCreated |
2009-8-17
|
|
pubmed:abstractText |
DNA vaccine represents an attractive approach for cancer treatment by inducing active immune-deprivation of gastrin-releasing peptide (GRP) from tumor cells, the growth of which is dependent on the stimulation of GRP. In this study, we developed a DNA vaccine using a plasmid vector to deliver the immunogen of six copies of the B cell epitope GRP(18-27) (GRP6). In order to increase the potency of this DNA vaccine, multiple strategies have been applied including DNA-prime protein-boost immunization and introduction of a foreign T-helper epitope into DNA vaccine. Mice vaccinated DNA vaccine boosting with HSP65-GRP6 protein induced high titer and relatively high avidity of anti-GRP antibodies as well as inhibition effect on the growth of murine prostate carcinoma, superior to the treatment using DNA alone or BCG priming HSP65-GRP6 protein boosting. Furthermore, the introduction of a novel foreign T-helper epitope into the GRP DNA vaccine showed a markedly stronger humoral immune response against GRP and tumor rejection even than the DNA-prime protein-boost strategy. No further stronger immunogenicity of this foreign T-helper epitope modified DNA vaccine was observed even using the strategy of modified DNA vaccine-priming and HSP65-GRP6 boosting method. The data presented demonstrate that improvement of potency of anti-GRP DNA vaccine with the above two feasible approaches should offer useful methods in the development of new DNA vaccine against growth factors for cancer immunotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, B-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/Gastrin-Releasing Peptide,
http://linkedlifedata.com/resource/pubmed/chemical/Heat-Shock Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, DNA,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/gastrin releasing peptide (18-27)...,
http://linkedlifedata.com/resource/pubmed/chemical/heat-shock protein 65, human
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1873-2518
|
|
pubmed:author |
pubmed-author:FangJingJ,
pubmed-author:HuXiangbingX,
pubmed-author:JinLiangL,
pubmed-author:LiuJingjingJ,
pubmed-author:LuYongY,
pubmed-author:MaYanjunY,
pubmed-author:OuyangKedongK,
pubmed-author:RongyueCaoC,
pubmed-author:TaimingLiL,
pubmed-author:WuGuojunG,
pubmed-author:YeoY MYM,
pubmed-author:ZhangHuiyongH,
pubmed-author:ZhangYuY
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
27
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5411-8
|
|
pubmed:meshHeading |
pubmed-meshheading:19616501-Adjuvants, Immunologic,
pubmed-meshheading:19616501-Animals,
pubmed-meshheading:19616501-Antibody Affinity,
pubmed-meshheading:19616501-Cancer Vaccines,
pubmed-meshheading:19616501-Carcinoma,
pubmed-meshheading:19616501-Cell Line,
pubmed-meshheading:19616501-Epitopes, B-Lymphocyte,
pubmed-meshheading:19616501-Epitopes, T-Lymphocyte,
pubmed-meshheading:19616501-Gastrin-Releasing Peptide,
pubmed-meshheading:19616501-Heat-Shock Proteins,
pubmed-meshheading:19616501-Male,
pubmed-meshheading:19616501-Mice,
pubmed-meshheading:19616501-Mice, Inbred C57BL,
pubmed-meshheading:19616501-Neoplasms, Experimental,
pubmed-meshheading:19616501-Peptide Fragments,
pubmed-meshheading:19616501-Prostatic Neoplasms,
pubmed-meshheading:19616501-Recombinant Fusion Proteins,
pubmed-meshheading:19616501-Vaccines, DNA,
pubmed-meshheading:19616501-Vaccines, Synthetic
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
|
|
pubmed:affiliation |
Minigene Pharmacy Laboratory, Biopharmaceutical College, China Pharmaceutical University, 24 Tongjia Xiang, Nanjing 210009, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
